The impact of AlphaFold on protein structure prediction has been transformative.
Apparatus
-
-
In a rural area of Britain, a team of 100 scientists and engineers first used low-cost technologies to develop mobile phones and the aviation industry. Later, these technologies were used to research robot arms, which can be specially used for minimally invasive surgery.
-
Apparatus
Fda Accepts Zuranolone's Nda Application And Grants It Priority Review For The Treatment Of Mdd And Pdd
Approval for new FIC depression drug on the horizon!
-
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
-
Apparatus
New Targeted Drug For Leukaemia Approved, 35% Of Patients' Cancer Cells Disappear Completely!
The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.
-
Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."
-
Apparatus
Angry FDA & CDC: $5 Billion Bivalent Moderna New Crown Vaccine Not As Effective As Monovalent
Was the omission of key data intentional or unintentional?
-
HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.
-
Apparatus
New CAR-T Therapy CB-010, Granted Two FDA Designations And Three Patients Are Cancer-Free For Six Months!
According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
Accelerating and simplifying the development and manufacturing process of cell and gene therapies.